| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1105486033 |
| P356 | DOI | 10.1186/S12935-018-0594-Z |
| P932 | PMC publication ID | 6042434 |
| P698 | PubMed publication ID | 30008616 |
| P50 | author | Francesca Battaglin | Q54963247 |
| Alberto Puccini | Q55590284 | ||
| Heinz-Josef Lenz | Q89668545 | ||
| P2093 | author name string | Madiha Naseem | |
| P2860 | cites work | HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice | Q26741253 |
| Potential biomarkers for esophageal cancer | Q26749416 | ||
| Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer | Q26774509 | ||
| MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients | Q26865275 | ||
| Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma | Q27024034 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application | Q28079309 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification | Q29618627 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer | Q30837184 | ||
| Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study | Q33440401 | ||
| Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. | Q50058854 | ||
| HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer | Q50064802 | ||
| Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2-positive gastric cancer patients | Q50160878 | ||
| Oncogenic mutations in gastric cancer with microsatellite instability. | Q51538176 | ||
| HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. | Q51541370 | ||
| Liquid biopsy provides new insights into gastric cancer. | Q52620413 | ||
| Outlooks on Epstein-Barr virus associated gastric cancer. | Q52720624 | ||
| Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. | Q53128686 | ||
| Evaluation of altered expression of miR-9 and miR-106a as an early diagnostic approach in gastric cancer. | Q53176896 | ||
| HER2 expression variability between primary gastric cancers and corresponding lymph node metastases. | Q53527417 | ||
| Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. | Q54578578 | ||
| HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. | Q54587084 | ||
| Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. | Q54989505 | ||
| Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites. | Q55066506 | ||
| Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome | Q79522451 | ||
| Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients | Q81353699 | ||
| Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes | Q83831946 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial | Q84078596 | ||
| Epstein-Barr virus-associated gastric cancer reveals intratumoral heterogeneity of PIK3CA mutations | Q33608197 | ||
| The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy? | Q33632116 | ||
| Distribution of somatic mutations of cancer-related genes according to microsatellite instability status in Korean gastric cancer | Q33833750 | ||
| MicroRNAs as potential biomarkers for gastric cancer | Q34168445 | ||
| Causes and consequences of microsatellite instability in gastric carcinogenesis. | Q34589660 | ||
| Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. | Q35108424 | ||
| Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma | Q35145369 | ||
| Epstein-barr virus in gastro-esophageal adenocarcinomas - single center experiences in the context of current literature | Q35218805 | ||
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 | ||
| Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences | Q35763725 | ||
| Epstein-Barr Virus MicroRNA Expression Increases Aggressiveness of Solid Malignancies | Q35777091 | ||
| The ErbB receptors and their ligands in cancer: an overview. | Q36108987 | ||
| Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. | Q36303653 | ||
| Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways | Q36307708 | ||
| Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort | Q36475722 | ||
| Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial | Q36892840 | ||
| Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity | Q36918993 | ||
| Trends in esophageal adenocarcinoma incidence and mortality. | Q37096847 | ||
| Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients | Q37135262 | ||
| HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 | ||
| Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial | Q37174690 | ||
| Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma | Q37190164 | ||
| Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab | Q37335124 | ||
| Oncogenic pathway combinations predict clinical prognosis in gastric cancer. | Q37357165 | ||
| Long non-coding RNA expression profile in human gastric cancer and its clinical significances | Q37360311 | ||
| Cell type-specific signaling function of RhoA GTPase: lessons from mouse gene targeting | Q37404956 | ||
| Circulating miRNA profile in esophageal adenocarcinoma | Q37447965 | ||
| Clinicopathologic Characteristics of Microsatellite Instable Gastric Carcinomas Revisited: Urgent Need for Standardization | Q37488484 | ||
| Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers | Q37537123 | ||
| Gastric Cancer Genomics: Advances and Future Directions. | Q37673604 | ||
| MicroRNAs and pharmacogenomics | Q37736453 | ||
| Targeting MET in cancer: rationale and progress | Q37978193 | ||
| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial | Q38099726 | ||
| Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. | Q38307191 | ||
| Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer | Q50057702 | ||
| Update on Epstein-Barr virus and gastric cancer (review). | Q38336778 | ||
| A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett's Esophagus | Q38634473 | ||
| Long noncoding RNAs as potential biomarkers in gastric cancer: Opportunities and challenges | Q38636282 | ||
| HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens. | Q38637319 | ||
| PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence | Q38649562 | ||
| Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. | Q38659483 | ||
| FGFR a promising druggable target in cancer: Molecular biology and new drugs. | Q38692628 | ||
| Molecular classification of gastric cancer | Q38727880 | ||
| Immunotherapy for gastric cancers: emerging role and future perspectives | Q38738652 | ||
| Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. | Q38748208 | ||
| New agents on the horizon in gastric cancer | Q38759129 | ||
| The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer | Q38788032 | ||
| Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. | Q38936367 | ||
| Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer | Q38997289 | ||
| HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. | Q39007646 | ||
| Predictive biomarkers along gastric cancer pathogenetic pathways | Q39170872 | ||
| HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study | Q39525000 | ||
| Trastuzumab in gastric cancer | Q39864629 | ||
| EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number | Q40105232 | ||
| HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells. | Q40201364 | ||
| Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. | Q40250083 | ||
| HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib | Q40490620 | ||
| FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival | Q40733626 | ||
| Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. | Q41038524 | ||
| Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer | Q41595482 | ||
| Targeting microRNAs with small molecules: from dream to reality | Q41827839 | ||
| HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH) | Q41880900 | ||
| Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy | Q41983246 | ||
| Molecular classification of esophagogastric junction carcinoma correlated with prognosis | Q42283228 | ||
| Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances | Q42353279 | ||
| Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer | Q43142381 | ||
| Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial | Q43712233 | ||
| HER2 in resected gastric cancer: Is there prognostic value? | Q44578051 | ||
| Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. | Q44783161 | ||
| CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus | Q45416558 | ||
| Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. | Q46108181 | ||
| Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. | Q46129222 | ||
| The role of miRNA and lncRNA in gastric cancer | Q47117573 | ||
| Liquid biopsies in gastrointestinal malignancies: when is the big day? | Q47372761 | ||
| Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. | Q47584566 | ||
| Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma | Q47632392 | ||
| A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification | Q47695585 | ||
| Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q47745009 | ||
| PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer | Q47838777 | ||
| Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma | Q47864236 | ||
| Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives | Q49663292 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 99 | |
| P577 | publication date | 2018-07-11 | |
| P1433 | published in | Cancer Cell International | Q1829859 |
| P1476 | title | Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. | |
| P478 | volume | 18 |
| Q90247887 | A novel positive feedback loop of linc02042 and c-Myc mediated by YBX1 promotes tumorigenesis and metastasis in esophageal squamous cell carcinoma |
| Q89879114 | HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies |
| Q61445358 | Long noncoding RNA PXN-AS1-L promotes non-small cell lung cancer progression via regulating PXN |
| Q93082677 | MALAT1 promotes gastric adenocarcinoma through the MALAT1/miR-181a-5p/AKT3 axis |
| Q64101409 | Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy |
| Q64101703 | WISP2 exhibits its potential antitumor activity via targeting ERK and E-cadherin pathways in esophageal cancer cells |
Search more.